A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US

References

• Lafeuille MH, Grittner AM, Fortier J, et al. Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics. Am J Health Syst Pharm 2015;72:378-89
   PubMed Web of Science ®Google Scholar
• Chong HY, Chaiyakunapruk N, DBCW, et al. Global economic burden of schizophrenia: a systematic review. Value Health 2014;17:A767
   PubMed Web of Science ®Google Scholar
• Heres S, Lambert M, Vauth R. Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics. Eur Psychiatr 2014;29:1409-13
   PubMedGoogle Scholar
• Cloutier M, Sanon Aigbogun M, Guerin A, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry 2016;77:764-71
   PubMed Web of Science ®Google Scholar
• Chong HY, Teoh SL, Wu DB, et al. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treatment 2016;12:357
   Google Scholar
• Huang A, Amos TB, Joshi K, et al. Understanding healthcare burden and treatment patterns among young adults with schizophrenia. J Med Econ 2018;21(10):1026-35
   PubMed Web of Science ®Google Scholar
• Kreyenbuhl J, Buchanan RW, Dickerson FB, et al. The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2009. Schizophr Bull 2010;36:94-103
   Google Scholar
• Joshi K, Pan X, Wang R, et al. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate. Curr Med Res Opin 2016:32:1873-81
   PubMed Web of Science ®Google Scholar
• Marcus SC, Zummo J, Pettit AR, et al. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm 2015;21:754-69
   PubMed Web of Science ®Google Scholar
• MacEwan JP, Forma FM, Shafrin J, et al. Patterns of adherence to oral atypical antipsychotics among patients diagnosed with schizophrenia. J Manag Care Spec Pharm 2016;22:1349-61
   PubMedGoogle Scholar
• Schennach R, Riedel M, Musil R, et al. Treatment response in first-episode schizophrenia. Clin Psychopharmacol Neurosci 2012;10:78
   PubMedGoogle Scholar
• Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial. JAMA Psychiatr 2015;72:822-9
   PubMed Web of Science ®Google Scholar
• Invega Sustenna (paliperidone palmitate) extended-release injectable suspension US prescribing information [Internet]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2015. Available at: http://www.janssencns.com/shared/product/invegasustenna/prescribing-information.pdf [Last accessed 1 May 2018]
   Google Scholar
• Pilon D, Muser E, Lefebvre P, et al. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia. BMC Psychiatry 2017;17:207
   PubMedGoogle Scholar
• Young-Xu Y, Duh MS, Muser E, et al. Impact of paliperidone palmitate versus oral atypical antipsychotics on health care resource use and costs in veterans with schizophrenia. J Clin Psychiatry 2016;77:e1332-e1341
   PubMed Web of Science ®Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services [Internet]. (2017, November 24). Medicaid Drug Rebate Program; 2017. Available at: https://www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/index.html [Last accessed 22 May 2018]
   Google Scholar
• Prices for brand-name drugs under selected Federal programs. Washington, DC: Congressional Budget Office; 2005. Available at: https://www.cbo.gov/sites/default/files/109th-congress-2005-2006/reports/06-16-prescriptdrug.pdf [Last accessed 9 May 2018]
   Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399-424
   PubMed Web of Science ®Google Scholar
• Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput 2009;38:1228-34
   Web of Science ®Google Scholar
• Higashi K, Medic G, Littlewood KJ, et al. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol 2013;3:200-18
   PubMedGoogle Scholar
• Fitch K, Iwasaki K, Villa KF. Resource utilization and cost in a commercially insured population with schizophrenia. Am Health Drug Benefits 2014;7:18-26
   PubMedGoogle Scholar
• Offord S, Wong B, Mirski D, et al. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. J Med Econ 2013;16(2):231-9
   PubMedGoogle Scholar
• Xiao Y, Muser E, Lafeuille M-H, et al. Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patients. J Comp Eff Res 2015;14:1-14
   Google Scholar
• Slade PE, Simoni-Wastila L. Forecasting Medicaid expenditures for antipsychotic medications. Psychiatric Serv 2015;66:713-18
   PubMed Web of Science ®Google Scholar
• Anderson JP, Icten Z, Alas V, et al. Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations. BMC Psychiatry 2017;17:346
   PubMed Web of Science ®Google Scholar
• Medicaid Benefits: Prescription Drugs. Henry J Kaiser Family Foundation; 2012. Available at: https://www.kff.org/medicaid/state-indicator/prescription-drugs/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D [Last accessed 7 August 2018]
   Google Scholar